Sequenom, Inc. (SQNM) - NASDAQ
  • Nov. 8, 2012, 5:17 PM
    Sequenom (SQNM): Q3 EPS loss of $0.26 misses by $0.02. Revenue $22.9M misses by $280K. (PR)
    | Nov. 8, 2012, 5:17 PM
  • Nov. 8, 2012, 12:10 AM

    Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP

    | Nov. 8, 2012, 12:10 AM
  • Nov. 7, 2012, 5:35 PM

    Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP

    | Nov. 7, 2012, 5:35 PM
  • Sep. 17, 2012, 6:40 PM

    Sequenom (SQNM) says it's completed its private offering of $130M aggregate principal amount of 5% convertible senior notes due 2017. The company plans to use the proceeds to fund the commercialization of the MaterniT21 PLUS laboratory-developed test, as well as for other general corporate purposes.

    | Sep. 17, 2012, 6:40 PM | 1 Comment
  • Sep. 11, 2012, 9:10 AM
    Premarket gainers: WSB +91%. SNSS +48%. CTIC +15%. NOK +7%. CRTX +7%. RBS +6%. PSTI +5%.
    Losers: NAVB -31%. PPO -12%. PANW -8%. SQNM -7%. PPHM -6%.
    | Sep. 11, 2012, 9:10 AM
  • Sep. 10, 2012, 5:38 PM

    Sequenom (SQNM) announces a $100M private offering of convertible senior notes due 2017, with a 30-day option to purchase up to an additional $20M to cover over-allotments. The company plans to use the proceeds to fund the commercialization of its MaterniT21 PLUS laboratory-developed test, as well as for R&D, capital expenditures, working capital and general administrative expenses. Shares -7.5% AH.

    | Sep. 10, 2012, 5:38 PM
  • Aug. 28, 2012, 9:16 AM

    Sequenom (SQNM) +3.9% premarket on news its subsidiary has completed several international distribution agreements that will expand access to the MaterniT21 PLUS testing service outside the U.S. MaterniT21 PLUS is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation.

    | Aug. 28, 2012, 9:16 AM
  • Aug. 16, 2012, 9:10 AM
    Premarket gainers: BTH +23%. VQ +17%. EA +10%. SINA +8%. CSTR +8%. OCZ +8%. CSCO +7%. SQNM +6%. PETM +6%.
    Losers: IDIX -39%. MCP -8%. NTES -8%. A -7%. DLTR -6%.
    | Aug. 16, 2012, 9:10 AM | 1 Comment
  • Aug. 3, 2012, 9:15 AM
    Premarket gainers: OPEN +19%. MELI +17%. SKUL +13%. LNKD +11%. ATPG +11%. VHC +10%. KOG +10%. KCG +10%. STEM +8%. SQNM +8%. DB +7%. ING +7%. WFR +7%. E +6%. SI +5%. MT +5%. ATAX +5%. BCS +5%.
    Losers: ZIP -35%. HNT -24%. BODY -18%. MCP -15%. XIDE -13%. REE -8%. GLUU -7%. ONNN -7%.
    | Aug. 3, 2012, 9:15 AM
  • Jul. 26, 2012, 6:27 PM
    Sequenom (SQNM): Q2 EPS of -$0.26 misses by $0.05. Revenue of $18.3M (+37.6% Y/Y) misses by $0.89M. Shares -3.8% AH. (PR)
    | Jul. 26, 2012, 6:27 PM
  • Jul. 6, 2012, 12:09 PM

    Sequenom (SQNM -4.2%) sinks after a California District Court denied its petition for an injunction against Ariosa Diagnostics to prevent the company from offering or selling its Harmony Prenatal Test, pending resolution of current litigation between the two companies.

    | Jul. 6, 2012, 12:09 PM
  • Jul. 6, 2012, 9:10 AM
    Premarket gainers: BOOT +81%. PCX +10%. JRCC +6%.
    Losers: INFA -30%. ALXA -11%. APKT -10%. AONE -8%. SQNM -6%.
    | Jul. 6, 2012, 9:10 AM
  • May 17, 2012, 5:24 PM

    Sequenom (SQNM) says the recently announced provider network participation agreement with Coventry Health Care (CVH) has been terminated without cause by Coventry. The agreement was intended to provide members in the network with coverage for Sequenom CMM's MaterniT21 PLUS laboratory-developed test. SQNM -7.8% AH.

    | May 17, 2012, 5:24 PM
  • May 9, 2012, 4:54 PM
    The big move higher in Zillow (Z) over the past 2 weeks takes on a bit more interest with the disclosure Stevie Cohen's SAC Capital has accumulated a 5% stake in the company. The hedge fund has also increased positions or taken new stakes in Sequenom (SQNM), Western Refining (WNR), YELP, and Walter Energy (WLT), among others.
    | May 9, 2012, 4:54 PM | 1 Comment
  • May 3, 2012, 8:29 PM
    Sequenom (SQNM): Q1 EPS of -$0.22 misses by $0.03. Revenue of $14.9M (+10.4% Y/Y) misses by $1.4M. Shares -3% AH. (PR)
    | May 3, 2012, 8:29 PM
  • Apr. 24, 2012, 5:46 PM
    Sequenom (SQNM) surged 9.4% today after a Wedbush analyst said results for its Maternit21 fetal genetic tests make it harder to argue that investors should short the stock. “SQNM has effectively met development and commercial launch milestones in the last 12 months and has driven significant test volume in the first six months of launch," the firm says.
    | Apr. 24, 2012, 5:46 PM
Company Description
Sequenom, Inc. provides early patient management information. It develops and commercializes molecular diagnostic testing services that serve women's health and oncology markets. The company was founded by Hubert Koester and Charles R. Cantor in 1994 and is headquartered in San Diego, CA.
Sector: Healthcare
Industry: Biotechnology
Country: United States